STOCK TITAN

Whitehawk Therapeutics: ABG V-SIV reports 7.8% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. (WHWK) is the issuer in an amended Schedule 13G/A reporting that several reporting persons, including ABG V-SIV Limited and Fan Yu, may be deemed to share beneficial ownership of 4,829,398 shares, or 7.8% of the class. Fan Yu is identified as the controlling stockholder of ABG Global Life Science Capital Partners V GP Limited. The reporting persons disclaim beneficial ownership of the securities.

The reported amount includes 1,619,472 shares held of record and 3,209,926 shares issuable upon currently exercisable warrants, subject to a 9.99% beneficial ownership limitation on exercise. Whitehawk had 59,008,982 shares outstanding as of November 5, 2026.

Beneficial ownership reported 4,829,398 shares Several reporting persons may be deemed to share beneficial ownership
Percent of class 7.8% As reported for the beneficially owned amount
Shares held of record 1,619,472 shares Held of record by ABG V-SIV Limited
Shares issuable upon warrant exercise 3,209,926 shares Warrants held of record by ABG V-SIV Limited; currently exercisable
Shares outstanding 59,008,982 shares As of November 5, 2026
Beneficial ownership limitation 9.99% Limitation on exercise of the warrants
beneficial ownership limitation regulatory
"subject to a 9.99% beneficial ownership limitation on exercise"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
beneficial ownership regulatory
"may be deemed to share beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
held of record financial
"shares of Common Stock held of record by ABG V-SIV Limited"
warrants financial
"warrants are currently exercisable"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much beneficial ownership was reported for WHWK?

Several reporting persons may be deemed to share beneficial ownership of 4,829,398 shares, or 7.8% of the class. The amount includes shares held of record by ABG V-SIV Limited and shares issuable upon exercise of its warrants; the reporting persons disclaim beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





00032Q104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ABG Management Ltd.
Signature:By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:11/16/2026
Ally Bridge Group (NY) LLC
Signature:By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:11/16/2026
Ally Bridge MedAlpha Master Fund L.P.
Signature:By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:11/16/2026
ABG Global Life Science Capital Partners V GP Limited
Signature:By: /s/ Shan-ju Yeh
Name/Title:Shan-ju Yeh, Director
Date:11/16/2026
ABG Global Life Science Capital Partners V GP, L.P.
Signature:By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Shan-ju Yeh
Name/Title:Shan-ju Yeh, Director
Date:11/16/2026
Ally Bridge Group Global Life Science Capital Partners V, L.P.
Signature:By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh
Name/Title:Shan-ju Yeh, Director
Date:11/16/2026
ABG-SIV, L.P.
Signature:By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh
Name/Title:Shan-ju Yeh, Director
Date:11/16/2026
ABG V-SIV Limited
Signature:By: /s/ Shan-ju Yeh
Name/Title:Shan-ju Yeh, Director
Date:11/16/2026
Fan Yu
Signature:/s/ Fan Yu
Name/Title:Fan Yu
Date:11/16/2026
Exhibit Information

Exhibit 99: Joint Filing Agreement (previously filed).

Keep reading